ArticleVirus research2026
The murine correlate of the Epstein-Barr and Kaposi's sarcoma-associated γ-herpesviruses, MHV-68, represents a valuable model to assess antiviral drug sensitivity and combinatorial drug synergies.
Article in Virus research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human herpesviruses represent major human pathogens. Members of the γ-Herpesvirinae subfamily are of particular interest because they cause chronic diseases, such as cancers, by altering cellular processes and driving resting cells into a continuously proliferating phase. Also, autoimmune diseases such as multiple sclerosis have continuously been in the focus of interest. The prototypic human γ-herpesvirus, Epstein-Barr virus (EBV), has proven difficult to analyze for the development of antiviral therapies due to challenges associated with propagating the virus in vitro, phenotyping it, and assessment of antiviral phenotypic efficacy. Similarly, developing experimental systems to study the second human pathogenic virus in this subfamily, Kaposi sarcoma-associated herpesvirus (KSHV), has been challenging. The murine γ-herpesvirus 68 (MHV-68) is a well-characterized homolog of EBV and KSHV and represents a model virus for cell culture-based and animal-specific analyses. Here, we used MHV-68 to determine virus sensitivity to antivirals, and combinatorial drug synergies. Much of the recent information about novel antiherpesviral drugs has come from studies of human cytomegalovirus (HCMV). Therefore, a comparative analysis was also conducted between HCMV, MHV-68, and EBV. The study demonstrated: (i) successful establishment of a new MHV-68 replication model in murine and non-murine cell types; (ii) optimization of an MHV-68-specific quantitative readout based on the luciferase reporter system; (iii) assessment of mechanistically novel antiherpesviral compounds; (iv) comparative antiviral effects spanning the three respective herpesviruses; (v) analysis of antiviral drug combination treatments able to identify statistically significant drug synergies. Overall, the study provides new insights into molecular aspects of γ-herpesvirus replication, as well as antiviral drug development and targeting strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.